Wave Life Sciences (WVE) Current Deferred Revenue (2014 - 2026)

Wave Life Sciences (WVE) has 12 years of Current Deferred Revenue data on file, last reported at $8.7 million in Q2 2026.

• Quarterly Current Deferred Revenue fell 83.13% year-over-year to $8.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.7 million (down 83.13% YoY) and the FY2025 annual result came in at $44.4 million, down 32.64% from the prior year.
• Current Deferred Revenue retreated to $8.7 million in Q2 2026, from $9.4 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $150.1 million in Q4 2023 to a low of $8.7 million in Q2 2026.
• A 5-year average of $70.7 million and a median of $54.4 million in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2023 — Current Deferred Revenue soared 375.5% — and 2026, when it slumped 83.61%.
• Tracing WVE's Current Deferred Revenue over 5 years: stood at $31.6 million in 2022, then soared by 375.5% to $150.1 million in 2023, then tumbled by 56.04% to $66.0 million in 2024, then slumped by 32.64% to $44.4 million in 2025, then slumped by 80.42% to $8.7 million in 2026.
• The last three Current Deferred Revenue figures came in at $8.7 million (Q2 2026), $9.4 million (Q1 2026), and $44.4 million (Q4 2025), per Business Quant data.